PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 21(6): 560-567 2001
© 2001 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krediet, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krediet, R.
Peritoneal Dialysis International, Vol 21, Issue 6, 560-567
Copyright © 2001 by International Society for Peritoneal Dialysis

Articles

Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis

RT Krediet

Department of Medicine, Academic Medical Center, University of Amsterdam, The Netherlands. M.A.Zeeman@amc.uva.nl

OBJECTIVE: This study reviews publications on the history of cancer antigen 125 (CA125), the background of its use as a marker of mesothelial cell mass, determination in peritoneal effluent, and its practical use in both the follow-up of peritoneal dialysis (PD) patients and as a marker of in vivo biocompatibility of dialysis solutions. DESIGN: Review article. RESULTS: CA125 is a high molecular weight glycoprotein. Previous studies in ascites suggested its release by mesothelial cells. In vitro studies with cultured mesothelial cells showed constitutive production, the majority of which was dependent on mesothelial cell mass. Serum CA125 is normal in PD patients, but its concentration in peritoneal dialysate suggests local release, probably from mesothelial cells. Effluent CA125 can be considered a marker of mesothelial cell mass in stable PD patients, but large amounts are found during peritonitis, due probably to necrosis of mesothelial cells. The majority of studies found no relationship between dialysate CA125 and peritoneal transport parameters. Some cross-sectional studies reported a relationship with duration of PD, but others were unable to confirm this, due probably to the large interindividual variability. Longitudinal follow-up has shown a decrease in dialysate CA125, indicating loss of mesothelial cell mass. Application of theoretically more-biocompatible PD solutions causes an increase in dialysate CA125. CONCLUSIONS: Dialysate CA125 is a mesothelial cell mass marker. The concentration of CA125 should be determined after a standardized dwell. A single low value is not informative. A decrease with time on PD suggests loss of mesothelial cell mass. Dialysate CA125 is a marker of in vivo biocompatibility of (new) dialysis solutions. More research is necessary on the best methodology for measuring low concentrations and establishing normal values and a significant change.




This article has been cited by other articles:


Home page
 NDT PlusHome page
A. M. Coester, M. M. Zweers, D. R. de Waart, and R. T. Krediet
The relationship between effluent potassium due to cellular release, free water transport and CA125 in peritoneal dialysis patients
NDT Plus, October 1, 2008; 1(suppl_4): iv41 - iv45.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. M. Coester, D. G. Struijk, W. Smit, D. R. de Waart, and R. T. Krediet
The cellular contribution to effluent potassium and its relation to free water transport during peritoneal dialysis
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3593 - 3600.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C.-C. Szeto, K.-M. Chow, C. W.-K. Lam, C.-B. Leung, B. C.-H. Kwan, K.-Y. Chung, M.-C. Law, and P. K.-T. Li
Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--A 1-year randomized control trial
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 552 - 559.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. J Manley, R. J Elwell, G. R Bailie, and C. L Welch
Intraperitoneal Cefazolin and Ceftazidime Effects on Human Peritoneal Mesothelial Cell Release of Cancer Antigen-125
Ann. Pharmacother., December 1, 2004; 38(12): 2035 - 2040.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Gillerot, H. Debaix, and O. Devuyst
Genotyping: a new application for the spent dialysate in peritoneal dialysis
Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1298 - 1301.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Witowski, K. Korybalska, K. Ksiazek, J. Wisniewska-Elnur, A. Jorres, C. Lage, T. P. Schaub, J. Passlick-Deetjen, A. Breborowicz, A. Grzegorzewska, et al.
Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells
Nephrol. Dial. Transplant., April 1, 2004; 19(4): 917 - 924.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Haas, C. P. Schmitt, K. Arbeiter, K.-E. Bonzel, M. Fischbach, U. John, A.-K. Pieper, T. P. Schaub, J. Passlick-Deetjen, O. Mehls, et al.
Improved Acidosis Correction and Recovery of Mesothelial Cell Mass with Neutral-pH Bicarbonate Dialysis Solution among Children Undergoing Automated Peritoneal Dialysis
J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2632 - 2638.
[Abstract] [Full Text] [PDF]

Home page
 J Ultrasound MedHome page
M. Garefalakis, J. P. Ludlow, A. J. McCartney, P. J. Hugo, and J. E. Dickinson
Tuberculous Peritonitis With Sonographic Features of an Ovarian Cystadenoma
J. Ultrasound Med., September 1, 2003; 22(9): 989 - 992.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2001 by Multimed Inc.